What is ENGN's current stock price?

ENGN (enGene Holdings Inc.) is currently trading at $1.70 with a market cap of $87.0M.

What sector is enGene Holdings Inc. in?

enGene Holdings Inc. (ENGN) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is ENGN a good stock to buy?

Analysts have a Hold consensus on ENGN with a price target of $9.57. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

ENGN enGene Holdings Inc.

Healthcare

$1.70+0.00%OpenMarket Cap: $87.0M

As of 2026-05-26

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

0.39

P/S

0.00

EV/EBITDA

-0.68

DCF Value

$0.28

FCF Yield

-123.6%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-55.8%

ROA

-36.3%

ROIC

-40.5%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-29.8M	$—
Q4 null	$0.00	$-37.9M	$—
FY null	$0.00	$-117.3M	$—
Q3 null	$0.00	$-29.0M	$—

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$9.57

Target (Median)

$4.00

Target Range

$2.00 - $28.00

2 Strong Buy7 Buy8 Hold0 Sell0 Strong Sell

UBSNeutral

2026-05-14

HC Wainwright & Co.Buy

2026-05-08

Wells FargoEqual Weight

2026-05-08

GuggenheimNeutral

2026-05-08

CitizensMarket Perform

2026-05-08

Trading Activity

Insider Trades

View All

Nichols Alexander Julianofficer: Chief Strategy & Ops. Ofc

SellTue Feb 03

Giguere Leeofficer: Chief Legal Ofc. and Corp Secy

SellTue Feb 03

Daws D. Ryanofficer: Chief Financial Officer

SellTue Feb 03

Cooper Ronald Harold Wilfreddirector, officer: CEO & President

SellTue Feb 03

Connolly Joanofficer: Chief Technology Officer

SellTue Feb 03

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

-0.01

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

Peers

ALT